9HA Stock Chart & Stats
€2.66
€0.04(1.53%)
At close: 4:00 PM EDT
€2.66
€0.04(1.53%)
Day’s Range― - ―
52-Week Range€2.32 - €12.40
Previous CloseN/A
Volume0.00
Average Volume (3M)50.00
Market Cap
€56.97M
Enterprise Value€194.08
Total Cash (Recent Filing)€14.95M
Total Debt (Recent Filing)€14.34M
Price to Earnings (P/E)―
Beta-0.61
Next Earnings
Aug 07, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding23,466,394
10 Day Avg. Volume0
30 Day Avg. Volume50
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.95Price Target Upside574.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biological Activity / Immune PrimingDemonstrated mKRAS-specific T-cell induction and rare complete responses indicate a credible mechanism and potential for durable tumor control when paired with checkpoint inhibitors. This biologic signal supports a rational combination strategy and raises the probability of a clinically meaningful product profile if replicated prospectively.
Focused Registrational StrategyManagement’s pivot to a narrower, R0 resected population and altered dosing regimen shows adaptive development planning. Targeting a higher-probability subgroup with a specific DFS endpoint can improve trial power and regulatory clarity, reducing execution risk across a 2–6 month planning horizon and into registrational timelines.
Incremental Financing To Advance ProgramsA $15M registered direct offering provides near-term runway to support planned Phase 1/Phase 3 activities and KOL engagement. While dilutive, this funding materially reduces immediate financing uncertainty and allows execution of key clinical milestones that determine long-term program value and partnership prospects.
Bears Say
No Revenue And Heavy Cash BurnAs a development-stage biotech with persistent negative free cash flow and no product revenue, the company depends on external financing to fund trials. Negative equity and sustained burn increase dilution risk and constrain strategic flexibility, making long-term program funding contingent on successful financings or partnerships.
Missed Phase 2 Primary EndpointFailure to meet the primary endpoint raises uncertainty about clinical efficacy at the program level. This increases the likelihood of additional or larger trials, more stringent regulatory scrutiny, and greater time and cost to approval, which stresses resources and raises financing requirements over the medium term.
Reliance On Post-hoc/subgroup SignalsKey positive signals stem from small numbers and post-hoc analyses, which are vulnerable to non-repetition. Replicating these results requires prospective, adequately powered studies; until then the program’s commercial and regulatory prospects remain speculative, increasing development and go-to-market risk.
Elicio Therapeutics News
9HA FAQ
What was Elicio Therapeutics’s price range in the past 12 months?
Elicio Therapeutics lowest stock price was €2.32 and its highest was €12.40 in the past 12 months.
What is Elicio Therapeutics’s market cap?
Elicio Therapeutics’s market cap is €56.97M.
When is Elicio Therapeutics’s upcoming earnings report date?
Elicio Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 2 days.
How were Elicio Therapeutics’s earnings last quarter?
Elicio Therapeutics released its earnings results on May 11, 2026. The company reported -€0.564 earnings per share for the quarter, missing the consensus estimate of -€0.403 by -€0.16.
Is Elicio Therapeutics overvalued?
According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued.
Does Elicio Therapeutics pay dividends?
Elicio Therapeutics does not currently pay dividends.
What is Elicio Therapeutics’s EPS estimate?
Elicio Therapeutics’s EPS estimate is -0.47.
How many shares outstanding does Elicio Therapeutics have?
Elicio Therapeutics has 23,466,394 shares outstanding.
What happened to Elicio Therapeutics’s price movement after its last earnings report?
Elicio Therapeutics reported an EPS of -€0.564 in its last earnings report, missing expectations of -€0.403. Following the earnings report the stock price went up 14.286%.
Which hedge fund is a major shareholder of Elicio Therapeutics?
Currently, no hedge funds are holding shares in DE:9HA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€17.95 (574.84% Upside)
€17.95 (574.84% Upside)
Blogger Sentiment
Bearish
DE:9HA Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.38%
Trailing 12-Months
Company Description
Elicio Therapeutics
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
9HA Stock 12 Month Forecast
Average Price Target
€17.95
▲(574.84% Upside)
Technical Analysis
Compugen
―
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―